

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

48-00537-03

Docket or Reference number

03-03406

Amendment No. 57

St. Joseph Hospital  
Department of Radiology  
and Pathology  
5000 West Chambers Street  
Milwaukee, WI 53210

In accordance with letter dated January 10, 1985, License Number 48-00537-03 is amended as follows:

Items 6., 7., 8., and 9. are amended to add:

6. Byproduct, source,  
and/or special nuclear  
material

7. Chemical and/or  
physical form

8. Maximum amount that  
licensee may possess  
at any one time  
under this license

P. Gadolinium-153

P. Sealed sources  
(Gulf Nuclear Model  
GD-1 contained in a  
Lunar Radiation Corp.  
lead-lined brass  
source holder)

P. 2 curies (2 sources  
not to exceed 1  
curie each)

9. Authorized Use

P. One source to be used as a component of Lunar Radiation Corporation Model DP3 spine/femur scanner for determining human bone mineral content. One source in its shipping container to be in possession of the licensee as necessary for replacement in the scanner.

Conditions 12. and 22. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

G. H. Altshuler, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133

Subitems 6.F through 6.L for  
laboratory studies including  
animal studies

Strontium-90 for dosimeter  
calibrations

Joseph F. Wepfer, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133

Subitems 6.F through 6.L for  
laboratory studies including  
animal studies

Strontium-90 for dosimeter  
calibrations

Gadolinium-153

B506030601 850510  
REG3 LIC30  
48-00537-03 PDR

COPY 2

ML3000

5-10-85

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

48-00537-03

Docket or Reference number

030-03406

Amendment No. 57

John P. Matsis, M.D.

Groups I, II, III, IV, V and VI  
Xenon-133

Subitems 6.F through 6.L for  
laboratory studies including  
animal studies

Strontium-90 for dosimeter  
calibrations

Cadmium-109

Stanton Marks, M.D.

Group VI

Douglas King, M.D.

Group VI

R. Finney, M.D.

Group VI

J. Korenic, M.D.

Group VI

Gerald M. Cullen, M.D.

Groups I, II, III and IV  
Xenon-133

Iodine-131 for treatment of  
thyroid carcinoma

Winston N. Hollister, M.D.

Licensed material of the types,  
quantities, and forms specified  
in Sections 35.31(a) of 10 CFR 35  
and 31.11(a) of 10 CFR 31 to be  
used in accordance with the  
provisions of (a) and (c) of  
Section 35.31, 10 CFR 35 and  
paragraphs (a), (c), and (d) of  
Section 31.11, 10 CFR 31.

22. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated May 29, 1979; and letters dated June 18, 1978, July 30, 1979, January 28, 1980 (received February 2, 1981), August 24, 1981, January 10, 1985 and April 3, 1985; and ALARA Program dated July 17, 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Condition 24. is added:

24. Sealed sources listed in Subitem 6.P. shall not be opened or removed from their respective source holders by the licensee.

For the U.S. Nuclear Regulatory Commission

Date May 10, 1985

Original Signed  
By R. J. Holt  
Materials Licensing Section, Region III  
COPY